Saturday 17 October 2026
Export CSBR’s income statement to Excel — free account
Champions Oncology, Inc.
CSBR Healthcare Biotechnology
Champions Oncology, Inc.’s revenue for fiscal 2026 (year ended April 2026) was $59.4 million, up 4.36% from fiscal 2025. In the quarter to July 2026, revenue grew 8.84%, EPS was flat and free cash flow fell 198.7%, each against the same quarter a year earlier.
4.70
0.09
−1.88%
Follow CSBR
| Apr '17 | Apr '18 | Apr '19 | Apr '20 | Apr '21 | Apr '22 | Apr '23 | Apr '24 | Apr '25 | Apr '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 908.00 | 0.00 | 414.29 | 190.75 | 0.00 | 0.00 | 20.43 | 0.00 |
Piotroski F-Score |
5 | 5 | 7 | 4 | 5 | 6 | 3 | 3 | 8 | 3 |
Altman Z-Score |
(11.01) | (7.13) | 0.53 | (0.10) | 2.11 | 0.98 | (0.82) | (2.50) | 0.76 | (0.02) |
P/S ratio |
1.82 | 2.36 | 3.80 | 2.85 | 3.44 | 2.05 | 1.22 | 1.31 | 1.72 | 1.39 |
Altman Z″-Score (non-manufacturers) |
(35.17) | (31.65) | (20.10) | (11.35) | (7.75) | (5.75) | (8.65) | (14.50) | (7.27) | (10.06) |
P/FCF ratio |
0.00 | 0.00 | 100.16 | 133.47 | 0.00 | 24.48 | 59.83 | 0.00 | 13.95 | 0.00 |
P/Operating CF |
70.60 | 5,300.10 | 408.60 | 35.92 | (71.20) | 126.50 | (95.11) | (36.18) | 14.22 | (41.26) |
Beneish M-Score |
(4.43) | (2.13) | (3.13) | (3.01) | (1.17) | (3.20) | (3.95) | (2.50) | (2.89) | (1.80) |
P/B ratio |
70.25 | 15,900.31 | 46.01 | 17.93 | 18.98 | 11.07 | 14.20 | 0.00 | 25.89 | 20.27 |
Price to Tangible BV |
0.00 | 0.00 | 65.63 | 19.19 | 19.88 | 11.49 | 15.30 | 0.00 | 28.42 | 22.08 |
EV/Sales |
1.61 | 2.32 | 3.69 | 2.59 | 3.32 | 1.87 | 1.04 | 1.26 | 1.55 | 1.31 |
EV/EBITDA |
0.00 | 0.00 | 113.96 | 0.00 | 87.99 | 41.08 | 0.00 | 0.00 | 14.21 | 327.69 |
EV/Operating CF |
(8.73) | (38.22) | 53.61 | 28.63 | (81.14) | 14.13 | 14.05 | (10.30) | 11.91 | (17.37) |
EV/FCF |
(6.88) | (19.11) | 97.11 | 121.43 | (27.49) | 22.31 | 50.72 | (9.06) | 12.57 | (15.50) |
Quick Ratio |
0.75 | 0.64 | 0.95 | 1.07 | 1.04 | 1.06 | 0.83 | 0.56 | 0.88 | 0.91 |
Current Ratio |
0.79 | 0.68 | 0.99 | 1.10 | 1.13 | 1.13 | 0.90 | 0.63 | 0.94 | 0.96 |
Net Debt/EBITDA |
0.49 | 0.84 | (3.70) | 10.96 | (3.02) | (4.03) | 3.36 | 0.48 | (1.58) | (20.56) |
Debt/Assets |
0.47% | 0.21% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.10 | 5.67 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
2.24 | 2.52 | 2.80 | 2.01 | 1.70 | 1.56 | 1.55 | 1.66 | 1.95 | 2.00 |
Operating CF/Net income |
0.41 | 0.83 | 14.55 | (1.39) | (4.64) | 11.86 | (0.74) | 0.84 | 1.57 | 3.81 |
Capex/Depreciation |
(4.56) | (3.41) | (1.38) | (1.91) | (2.77) | (1.47) | (1.28) | (0.45) | (0.24) | (0.39) |
| (2,157.99%) | (732.51%) | 11.42% | (57.05%) | 5.78% | 6.63% | (77.70%) | (532.46%) | 503.05% | (29.97%) | |
| (99.85%) | (18.35%) | 1.32% | (13.07%) | 1.50% | 1.74% | (15.31%) | (24.08%) | 16.08% | (3.96%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 8.35% | 426.26% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
1,901.66% | 476.13% | 5.24% | (40.36%) | 4.81% | 5.88% | (108.66%) | 333.61% | 163.23% | (41.62%) |
Average Days of Receivables |
53.86 | 70.63 | 59.02 | 54.20 | 62.13 | 70.70 | 54.28 | 69.32 | 71.82 | 80.94 |
Research and Development Expense of Revenue |
27.86% | 21.74% | 17.73% | 18.22% | 17.53% | 19.09% | 21.43% | 19.03% | 11.99% | 15.29% |
Selling, General and Administrative Expense of Revenue |
53.36% | 32.81% | 28.57% | 33.80% | 29.32% | 31.55% | 32.01% | 36.15% | 29.65% | 34.45% |
Intangible Assets out of Total Assets |
0.08 | 0.08 | 0.06 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Share Based Compensation of Revenue |
17.27% | 4.96% | 2.35% | 1.87% | 1.46% | 1.86% | 1.60% | 2.23% | 1.15% | 2.08% |
Graham Net Nets |
(0.06) | (0.06) | (0.01) | (0.02) | (0.05) | (0.07) | (0.16) | (0.22) | (0.06) | (0.04) |
Graham Number |
0.00 | 0.00 | 0.21 | 0.00 | 0.57 | 0.79 | 0.00 | 1.31 | 1.47 | 0.00 |
Earnings Yield |
(25.10%) | (3.15%) | 0.11% | (2.20%) | 0.24% | 0.52% | (8.05%) | (11.13%) | 4.90% | (1.34%) |
Free Cash Flow Yield |
(12.83%) | (5.14%) | 1.00% | 0.75% | (3.52%) | 4.08% | 1.67% | (10.61%) | 7.17% | (6.08%) |
Revenue per Share |
1.44 | 1.84 | 2.39 | 2.71 | 3.12 | 3.72 | 3.98 | 3.70 | 4.17 | 4.30 |
Operating CF per Share |
(0.27) | (0.11) | 0.16 | 0.25 | (0.13) | 0.49 | 0.29 | (0.45) | 0.54 | (0.32) |
Capex per Share |
(0.07) | (0.11) | (0.07) | (0.19) | (0.25) | (0.18) | (0.21) | (0.06) | (0.03) | (0.04) |
Free Cash Flow per Share |
(0.34) | (0.22) | 0.09 | 0.06 | (0.38) | 0.31 | 0.08 | (0.51) | 0.51 | (0.36) |
Cash per Share |
0.31 | 0.08 | 0.29 | 0.70 | 0.36 | 0.68 | 0.75 | 0.19 | 0.72 | 0.35 |
Shareholders Equity per Share |
0.04 | 0.00 | 0.20 | 0.43 | 0.57 | 0.69 | 0.34 | (0.14) | 0.28 | 0.29 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.04 | 0.00 | 0.20 | 0.43 | 0.57 | 0.69 | 0.34 | (0.14) | 0.28 | 0.29 |
Free Cash Flow |
(3.61) | (2.45) | 1.03 | 0.69 | (4.96) | 4.11 | 1.10 | (6.97) | 7.00 | (5.01) |
Working Capital |
(1.58) | (2.39) | (0.10) | 1.19 | 1.43 | 2.19 | (2.28) | (7.90) | (1.49) | (0.70) |
Capital Expenditures |
(0.77) | (1.23) | (0.83) | (2.22) | (3.28) | (2.38) | (2.87) | (0.84) | (0.39) | (0.54) |
Net Current Asset Value |
(1.74) | (3.01) | (1.10) | (2.15) | (7.53) | (6.62) | (10.22) | (14.40) | (6.21) | (3.70) |
EV/EBIT |
0.00 | 0.00 | 369.72 | 0.00 | 372.65 | 151.20 | 0.00 | 0.00 | 19.32 | 0.00 |
Capex to Sales |
0.05 | 0.06 | 0.03 | 0.07 | 0.08 | 0.05 | 0.05 | 0.02 | 0.01 | 0.01 |
Price to Operating Income |
0.00 | 0.00 | 381.36 | 0.00 | 385.20 | 165.89 | 0.00 | 0.00 | 21.45 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.14 | 0.17 | 0.24 | 0.29 | 0.19 | 0.23 | 0.31 | 0.33 | 0.37 | 0.39 |
Cash ROIC |
(96.60%) | (279.91%) | 18.78% | 5.10% | (40.96%) | 22.72% | 7.46% | (975.24%) | 51.61% | (56.06%) |
Accounts Receivable Turnover |
8.60 | 6.54 | 6.53 | 7.02 | 6.98 | 5.95 | 6.15 | 5.72 | 5.49 | 4.87 |
Accounts Payable Turnover |
5.18 | 5.27 | 5.75 | 5.72 | 8.52 | 9.93 | 7.20 | 5.28 | 5.65 | 5.54 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
69.67 | 74.50 | 71.82 | 67.42 | 32.23 | 44.30 | 65.93 | 72.00 | 54.62 | 81.54 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
1.79 | 3.10 | 4.15 | 4.57 | 5.88 | 8.25 | 8.76 | 8.77 | 10.37 | 12.19 |
Average Payables |
1.87 | 2.00 | 2.48 | 2.97 | 2.52 | 2.38 | 4.10 | 5.57 | 5.02 | 5.58 |
Average Assets |
6.89 | 8.04 | 9.67 | 16.01 | 24.17 | 31.48 | 34.84 | 30.22 | 29.24 | 29.67 |
Average Common Equity |
0.32 | 0.20 | 1.12 | 3.67 | 6.26 | 8.26 | 6.87 | 1.37 | 0.93 | 3.92 |
Columns are period end dates